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2. CLINICAL PRESENTATION AND TREATMENT OF HIV - TB 
Soumya Swaminathan 
The HIV epidemic has increased the burden 
of tuberculosis (TB) among young adults, especially 
in populations where the prevalence of TB infection 
is high. Infection with HIV is the most potent risk 
factor for progression to active tuberculosis. 
Individuals who are infected with Mycobacterium 
tuberculosis only have an approximately 10% lifetime 
risk of developing active tuberculosis, compared with 
60% or more in persons infected with HIV and TB. 
This is particularly important in India where more 
than half the adult population harbours M. 
tuberculosis. It is estimated that there are about 14 
million cases oftuberculosis in India, about 2 million 
new cases occur annually, and we are home to 1 /  
4th the world’s TB prevalence. The situation is likely 
to get worse as the prevalence of HIV in the 
community increases. Therefore, it is important to 
understand the effect of TB and HIV on each other 
and take adequate measures to control this dual 
epidemic. Tuberculosis is the commonest 
opportunistic infection in HIV/AIDS patients with 
an attack rate of 7 per 100 person-years1. The sero- 
prevalence of HIV among TB patients in India varies 
widely2,3 and many studies have reported increasing 
reflecting the spread of HIV in the general 
population. Most cases of tuberculosis in HIV 
infected patients are due to reactivation of previous 
lesions. However, HIV infection also greatly increases 
the risk of developing TB following fresh infection, 
and the actual proportion of each type in India needs 
further study. Tuberculosis may occur at any time 
after HIV infection, but becomes more common as 
the immune system weakens. 
The clinical presentation of TB among the 
HIV infected is dependent on the degree of immune 
suppression. Patients with relatively preserved 
immune function, with CD4+ T cell counts above 
200/cu.mm are more likely to have typical symptoms, 
upper lobe disease and sputum smears positive for 
AFB. Patients who are severely immunosuppressed 
are more likely to have atypical clinical and 
radiographic features: extra-pulmonary disease 
including meningitis and miliary TB is also more 
common in the later stages of the disease. The 
absence of cavitation and combined pulmonary and 
extra-pulmonary disease are seen more often in 
patients with lower CD4 counts6. The symptoms of 
TB are similar to those of many other opportunistic 
infections and a thorough work-up may be required 
to establish the diagnosis. 
DIAGNOSIS 
An HIV positive patient with any of the 
following symptoms should be suspected of having 
TB and investigated further : 
Cough of more than 2 weeks’ duration. 
Fever lasting more than 2-3 weeks 
Weight loss 
Fatigue, listlessness 
Unexplained dyspnoea or chest pain 
Hemoptysis 
Lymph node enlargement (especially 
localised enlargement) 
Headache, vomiting, alteration of sensorium 
or convulsions. 
Physical examination should include search 
for pallor, enlarged lymph nodes, localized respiratory 
signs, hepatosplenomegaly, ascites and neurological 
signs. Oral thrush and emaciation are common 
accompanying signs. 
Sputum smear positivity among HIV positive 
patients is less than in HIV negative TB 
However, we have found similar sputum smear 
positivity among the culture confirmed HIV 
seropositive and seronegative tuberculosis patients 
( unpublished observation). Severe immuno 
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suppression among HIV infected patients with 
pulmonary tuberculosis is associated with a high 
bacillary load; such patients are less likely to have a 
granulomatous response in the lung tissues to M. 
tuberculosis. less cavitation and excretion of fewer 
bacilli from the lungs. Among HIV-infected persons, 
there is not only need for an early and accurate 
diagnosis of smear positive TB, to prevent further 
spread of infection in the community. but there is a 
need to accurately diagnose and treat smear negative 
cases as we1l to prevent progression to infectiousness. 
'Globally, and under RNTCP. a diagnostic algorithm 
based on response to antibiotics is used to improve 
the specificity of diagnosis of smear-negative 
tuberculosis9. 
INVESTIGATIONS 
The initial investigations should include: 
Chest X-ray - Radiographic abnormalities 
met with are parenchymal infiltrates, hilar or 
mediastinal lymph node enlargement, miliary mottling 
and pleural effusion. The lesions may be bilateral 
and extensive or minimal. Cavitation and upper lobe 
disease are relatively uncommon. A normal chest 
Xray does not exclude the diagnosis of tuberculosis. 
Sputum smear examination for AFB i.e. 
three specimens, including two over-night collections 
of sputum, should be obtained for AFB smear and 
culture tests. Smear examination by ZN or auramine- 
rhodamine (fluorescent) staining is the simplest test 
to perform. In our experience, over 70% of patients 
with HIV and culture confirmed pulmonary TB had 
positive smears. In the case of a negative result, 3 
more specimens should be collected and examined. 
Mycobacterial culture increases the chance of 
isolating M. tuberculosis from specimens but takes 
a long time (6-8 weeks), requires special 
microbiological facilities and is not widely available. 
The BACTEC radiometric method significantly 
reduces the time required for culture (10 to 14 days) 
but is expensive. 
Tuberculin skin test (Mantoux test) - This 
test does not play a major role in diagnosis of 
tuberculosis as 60% of adults in India are tuberculin 
positive. We have found that about 50% of the 
Indian Journal of Tuberculosis 
asymptomatic HIV+ persons are tuberculin positive' 
i.e. have more than 5 mm reaction with 1 TU of 
PPD RT 23. A positive Mantoux test only indicates 
infection with M. tuberculosis and not necessarily 
active disease; besides, tuberculous disease may 
occur in the absence of a positive reaction. In the 
late stages of HIV, the tuberculin test may be negative 
because of anergy but anergy testing with a panel of 
antigens (tetanus. mumps, Candida) is not 
recommended as the results are not reproducible. 
Depending on the clinical manifestations, the 
following additional investigations may be required: 
Examination ofclinical specimens from non- 
pulmonary sites e.g. blood, urine, CSF, stool and 
bone marrow for AFB, if extra-pulmonary TB is 
suspected. 
Fine needle aspiration cytology of enlarged 
lymph nodes (FNAC) 
CT scan of chest for presence of enlarged 
lymph nodes or parenchymal lesions that are not 
visible on plain X-ray. 
Induced sputum/gastric lavage: inhalation 
of nebulised hypertonic saline or Salbutamol 2 mg 
given three times daily for a week are used in order 
to induce sputum production. Gastric lavage can be 
performed in patients unable to expectorate. These 
specimens are tested for AFB by smear and culture. 
Flexible fibreoptic bronchoscopy with 
lavage (BAL) and transbronchial biopsy: Though BAL 
in itself is not better than sputum test for AFB, it 
may help to rule out other infections like 
Pneumocystis carinii. 
Total lymphocyte and CD4 counts: The 
percentage and absolute number of CD4 cells in blood 
provide a good index of the stage of HIV disease 
and have a prognostic value, especially when 
considered with the extent of viral load. Tuberculosis 
also produces a decline in CD4+ T cells, thereby 
worsening the immunologic status. Further, at very 
low CD4+ cell counts, the manifestations of 
tuberculosis may be atypical and a high index of 
suspicion is required for making a diagnosis. Hence, 
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the CD4 count, if available, is useful in assessing the 
prognosis as well as for recommending anti-retroviral 
treatment. The absolute lymphocyte count has been 
found to correlate broadly with the CD4 count and 
has been recommended as a cheaper alternative to 
CD4 testing. A total lymphocyte count of < 1500 
cells/cu.mm may indicate a CD4 count of < 200 cells/ 
cu.mm. 
The following newer diagnostic techniques 
are also available: 
BACTEC: This is a radiometric culture 
system using an enriched liquid medium which 
shortens the time required for culture and sensitivity 
testing to 2 weeks, However, it is expensive as the 
culture medium has to be imported and the facility is 
only available in major cities. The sensitivity of 
BACTEC has been found to be similar to conventional 
culture. The BACTEC technique may be useful for 
the diagnosis of mycobacteremia as a cause of 
unexplained fever (PUO) in HIV+ persons. 
PCR (Polymerase chain reaction): This is a 
rapid and sensitive technique to detect the nucleic 
acid of tubercle bacilli in clinical specimens. 
However, this technique is still under evaluation and 
its role in the clinical management of HIV-TB has 
not yet been finally determined. Further, the 
commonly used DNA probe IS6110 has a lower 
sensitivity for south Indian strains because of the 
lower copy number of insertion sequence. However, 
a combination of primers may improve the sensitivity 
of this assay. 
Serologic assays for antimycobacterial 
antibodies are not presently promising. both in HIV 
infected and non infected patients. 
TREATMENT 
If the results from investigations are not 
conclusive and TB is just a diagnostic possibility, a 
trial o f  broad spectrum antibiotics (e.g. Co- 
trimoxazole) may be given for 2 weeks and the patient 
may be re-assessed. If the X-ray lesion is persistent 
or has deteriorated, then TB is a strong possibility. 
In addition, sputum smears may become positive for 
AFB after a few weeks. 
Response of patients to Short Course Chemotherapy 
In  the past decade, several studies have 
examined the effectiveness of SCC for HIV infected 
patients. Although optimal treatment of tuberculosis 
among HIV infected patients is crucial, current 
knowledge and recommendations for duration of 
treatment are inconclusive. In a randomized trial in 
Zaire, the relapse rate of patients treated for 6 months 
was 9% as compared w i t h  1.9% among those treated 
for 12 months10. In a prospective study, a shorter 
duration of treatment and low CD4 cell counts were 
found associated with a higher risk of relapse". 
Relapses were seen in 3.4% of patients treated for 9 
months or more (1.7/100 patient-years) and in 24% 
of patients who were treated for less than 9 months 
(10.9/100 patient-years). A randomized trial of 6 
vs. 9 months of therapy. however, showed acceptable 
relapse rates, approximately 2%. in both groups'?. 
Several other studies have shown that treatment for 
6 months leads to high cure rates13-15. The American 
Thoracic Society/Centres for Disease Control 
recommend a 6-month duration of treatment unless 
the patient is slow to respond to anti-TB treatment16, 
replacing the earlier recommendation (treatment for 
at least 9 months). The IUATLD also recoinmends 
standard SCC regimens for the treatment of HIV 
associated tuberculosis". 
Recently, the effect of Trimethoprim- 
Sulfamethoxazole (Co-trimoxazole) in significantly 
decreasing mortality and hospital admission rates in 
HIV infected patients with tuberculosis has been 
demonstrated18. Another study has suggested that 
post- tr e at m en t m ai n t e n anc e therapy with a 
Combination of Isoniazid and Sulfadoxine- 
Pyrimethamine significantly reduces recurrence rates 
and decreases mortality following short-course 
chemotherapy19. 
The Revised National TB Control 
Programme (RNTCP) of India advocates treating 
new sputum positive TB patients with a 6 month 
supervised intermittent short course regimen 
(2EHRZ3/4RH3). Patients who have relapsed or failed 
or have taken more than 1 month of previous 
chemotherapy are to be treated with an 8 month 
intermittent regimen (2SHRZE3/1EHRZ3/5SEHR3). 
These regimens should be given under observation, 
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at least in the initial intensive phase of DOTS (Directly 
observed treatment, short course). DOTS providers 
can be either health workers or volunteers from the 
community. Under RNTCP, the HIV/TB patients are 
currently being treated with the standard regimens, 
but the effectiveness of these regimens in this group 
in the Indian context has not been ascertained. The 
efficacy of these regimens in patients with HIV and 
TB is currently being evaluated in a controlled clinical 
trial at the Tuberculosis Research Centre, Chennai. 
. In Haiti. however. the cure rate was 81% among 
HIV positives as against 87% among HIV negative 
TB patients20,21. 
Treatment of patients with drug resistance 
Drug resistance to single and multiple drugs 
is increasing in the community, mainly due to wrong 
prescriptions by doctors and poor compliance by 
patients. Drug resistant tuberculosis in HIV infected 
patients is no greater than in the general population, 
in developing countries. I f  the patient has INH 
resistant Mycobacterium tuberculosis, the response 
to standard short course regimens is usually good 
but presence of INH & Rifampicin resistance (MDR- 
TB) is associated with treatment failure rates upto 
70% and a high mortality. Hence, for MDR-TB, at 
least 3 effective drugs should be used (preferably 4 
or 5 )  based on drug susceptibilities or past treatment 
history. The duration of therapy is 18-24 months or 
at least 6 months after sputum conversion. The drug 
regimen and duration of therapy in cases of MDR- 
TB should be determined by experienced physicians. 
Evaluation of Response to Treatment 
The most effective means of assessing 
therapeutic response is through monthly sputum tests 
smears and cultures for AFB. More than 85% of 
patients will convert from positive to negative status 
after 2 months of therapy which includes INH and 
Rifampicin. Persistently positive smears after 4 
months of therapy suggest the possibility of disease 
due to drug resistant organisms or non-compliance 
with therapy. Patients who convert should have at 
least one additional smear and culture done before 
completion of therapy. A follow up chest radiograph 
can also be obtained at completion of treatment. 
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In patients who were treated presumptively, 
with negative sputum smears and cultures, the 
response to therapy should be evaluated clinically 
and with a follow-up chest X-ray at 3 months. Failure 
of radiographic improvement after three months of 
therapy should lead to  re-examination of  the 
diagnosis. Evaluation of response to treatment of 
extra-pulmonary TB will have to be individualized 
according to the site and extent of disease. 
Drug toxicity and Monitoring of treatment 
Adverse events with anti-tuberculosis drugs 
are more frequent in HIV infected patients. This is 
partly due to multiple medications these patients may 
be taking. Only serious or life threatening side effects 
warrant the discontinuation of therapy and most 
cases can be managed symptomatically. 
Thioacetazone should not be given to HIV positive 
patients as there is a high incidence of severe 
reactions including Stevens-Johnson syndrome. 
which may be fatal. Drug interactions between anti- 
TB drugs and other medications can also occur e.g. 
concomitant use of protease inhibitors results in high 
serum levels of Rifampicin and lower levels of 
protease inhibitors. Similarly, serum levels of anti- 
fungal agents like fluconazole and ketoconazole are 
lower when given along with Rifampicin. 
Preventive therapy 
Preventive therapy (PT) of TB with one or 
more anti-tuberculosis drugs is advocated to prevent 
progression to active disease of latent focii. HIV is 
the major cause of such progression. Several studies 
have now demonstrated that PT is effective in  
preventing TB breakdown in individuals dually 
infected with HIV and M tuberculosis 22-27. Studies 
conducted in USA, Africa and Haiti indicate that 
preventive therapy is efficacious in HIV positive 
persons with tuberculin reaction > 5mm, and that 
the duration of preventive Isoniazid therapy should 
be longer than six months. Recently, a two-month 
regimen of daily Rifampicin and Pyrazinamide was 
found to provide protection equivalent to daily 
Isoniazid for one year25. Intermittent 2 to 3-month 
regimen of Rifampicin and Pyrazinamide has also 
been recommended 26,27. The advantage of shorter 
duration regimens is better patient compliance and 
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possibly earlier sterilization of lesions; however, the 
risk of drug toxicity may be higher. The efficacy 
of preventive therapy in tuberculin negative HIV 
positive persons has not been clearly established; 
most studies show it to be of limited value. 
Several issues regarding preventive 
therapy for tuberculosis in HIV positive persons 
need to be addressed in the Indian setting. Due 
to the high risk of exposure to M tuberculosis. it 
is likely that HIV positive persons are at increased 
risk due to both reactivation and re-infection. 
Hence, HIV infected persons who are tuberculin 
negative could also be at a high risk of developing 
tuberculosis fo l Iowing  primary infection. 
Therefore. there is a need to evaluate the efficacy 
of prophylaxis for tuberculosis in both tuberculin 
positive and negative individuals. The duration of 
preventive therapy in an endemic setting is another 
area requiring further investigation. If risk of re- 
infection remains high, then short-term preventive 
treatment may be of limited benefit. Currently, 
preventive therapy is not a part of the RNTCP. 
However, the growing problem of HIV in India 
could make prevention of tuberculosis in this 
high-risk group a priority area in the years to 
come. 
Impact of Tuberculosis on HIV Infection 
Clinical  s tud ies  have shown the 
detrimental effect of tuberculosis on the course 
of HIV  infection 28. The risk of death in HIV 
infected persons with TB is reported to be twice 
as high as that in HIV infected patients without 
tuberculosis. The higher mortality rate is due to 
progressive AIDS rather than tuberculosis. M. 
tuberculosis probably increases viral replication 
by inducing macrophages to produce tumour 
necrosis factors, IL-1 and IL-6. The degree of 
immunosupression is the most important predictor 
o f  survival in HIV infected patients with 
tuberculosis. The widespread use of anti-retroviral 
therapy in the United States has reduced the 
number of cases of  tuberculosis among HIV- 
infected persons29. Thus, an improved access to 
anti-retroviral drugs could lead to significant 
public health benefit, especially in high HIV and 
TB prevalence areas. 
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